Grünwald, Viktor http://orcid.org/0000-0003-2083-7687
Voss, Martin H.
Rini, Brian I.
Powles, Thomas
Albiges, Laurence
Giles, Rachel H.
Jonasch, Eric
Funding for this research was provided by:
Pfizer (not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable)
Article History
Received: 18 March 2020
Revised: 12 May 2020
Accepted: 4 June 2020
First Online: 26 June 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: V.G. received commercial research grants from AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer and MSD; travel/accommodation costs from Bristol-Myers Squibb, Ipsen, Roche, Pfizer and AstraZeneca; was a consultant/advisory board member for AstraZeneca, Bayer, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Pfizer, MSD, Lilly, PharmaMar, Novartis, Nanobiotix, Merck KGaA/EMD Serono, Janssen-Cilag, Exelixis, Roche, Eisai and Cerulean. M.H.V. received commercial research grants from Bristol-Myers Squibb, Pfizer and Genentech/Roche; honoraria from Novartis; travel/accommodation costs from Eisai, Novartis, Takeda and AstraZeneca; was a consultant/advisory board member for Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis and Pfizer. E.J. received commercial research grants from Exelixis, Novartis and Pfizer; was a consultant/advisory board member for Eisai, Exelixis, Genentech, Ipsen, Novartis and Pfizer. T.P. received research funding from AstraZeneca, Roche, MSD, Bristol-Myers Squibb; was a consultant/advisory board member for Novartis, Bristol-Myers Squibb, Ipsen, Roche, Pfizer, Astellas Pharma, Seattle Geneticis, Merck, MSD, AstraZeneca, Exelixis and Peloton Therapeutics. L.A. received research funding from Bristol-Myers Squibb; was a consultant/advisory board member for Novartis, Amgen, Bristol-Myers Squibb, Ipsen, Roche, Pfizer, Astellas Pharma, Merck, MSD, AstraZeneca, Exelixis, Corvus Pharmaceuticals and Peloton Therapeutics; received travel, accommodations and expenses from Bristol-Myers Squibb and MSD. R.H.G. is the volunteer chair of a nonprofit organisation that receives designated project funding from Pfizer, Bristol-Myers Squibb, Ipsen, Eisai, Exelixis, MSD, Novartis, Roche, Merck and the Merck/Pfizer Alliance. She has not received any funds personally from any of the above. B.I.R. received a research grant and personal fee from Pfizer, Merck, Bristol-Myers Squibb, AVEO Pharmaceuticals and Roche. He received personal fees from Surface Oncology, Aravive, Synthorx and 3D Medicines.
: The advisers who participated in the meeting to discuss the need for differential therapy management guidelines received honoraria from Pfizer for their participation. Support for the literature analysis and medical writing was funded by Pfizer and Merck KGaA. Pfizer and Merck KGaA had no active role in the development of the guidelines reported in this paper. Open access funding provided by Projekt DEAL.